Wittbrodt, Eric

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study

Heerspink, H. J. L., Karasik, A., Thuresson, M., Melzer-Cohen, C., Chodick, G., Khunti, K., Wilding, J. P. H., Garcia Rodriguez, L. A., Cea-Soriano, L., Kohsaka, S., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 317

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 107

Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence

McEwan, P., Bennett, H., Khunti, K., Wilding, J., Edmonds, C., Thuresson, M., Wittbrodt, E., Fenici, P., & Kosiborod, M. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 58

Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: the enhancing outcomes through goal assessment and generating engagement in diabetes mellitus (ENGAGE-DM) pragmatic randomized trial

Lauffenburger, J. C., Ghazinouri, R., Jan, S., Makanji, S., Ferro, C. A., Lewey, J., Wittbrodt, E., Lee, J., Haff, N., Fontanet, C. P., et al. (2019) · PLOS ONE

Diabetes Management and EducationMedication Adherence and Compliance

Cited by 50